Clover, Chengda IPOs Add To $1.2bn Raised By Chinese Bioventures
Executive Summary
The listings of two vaccine manufacturers and fundraisings by seven other biopharma ventures generate around $1.2bn in new financing for Chinese companies focusing on a broad variety of therapeutic areas and indicating continued investor interest.
You may also be interested in...
BeiGene To Become First Tri-Listed Biotech Amid Offer Price Concerns
Nasdaq, Hong Kong and soon Shanghai, major Chinese firm BeiGene will be listed on three stock markets globally. But the high offer price of its imminent debut on China's STAR Market has raised concern among some investments and involved the use of a rare mechanism in the country.
Pharma Execs Urge 'Balance' In China Payer Price Negotiations
The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.
Chinese Biotechs Raise $212m Through Major VC/PE Deals in November
Leading the group were Trinomab Biotech, which develops antibodies for infectious diseases, and cell and gene developers BRL Medicine and XellSmart.